Press Releases
  Date Title View
Apr 28, 2016
SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2016, before the market opens ...
Apr 18, 2016
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress™ 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. The pr...
Apr 15, 2016
SAN DIEGO, April 15, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented today at The Internat...
Apr 5, 2016
SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York.  An audio we...
Apr 4, 2016
SAN DIEGO, April 04, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of Edward F. Smith III, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assu...
Mar 30, 2016
- Late Breaker Oral Presentation of Phase 2 Liver Cirrhosis Trial Three-month Data - - Poster of Preclinical Data Addressing Safety of Caspase Inhibition in Cancer Treatment - SAN DIEGO, March 30, 2016 (GLOBE NEWSWIRE) -- Conatus Ph...
Mar 9, 2016
SAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31, 2015, and provided updates on i...
Mar 2, 2016
SAN DIEGO, March 02, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2015, after th...
Feb 3, 2016
SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH). Based on ad...
Feb 2, 2016
SAN DIEGO, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 3:00 p.m. ET on Tuesday, February 9, 2016. An au...
FirstPrevious
3
...
NextLast
= add release to Briefcase